IL288755A - Compositions and methods for biological delivery vehicles - Google Patents

Compositions and methods for biological delivery vehicles

Info

Publication number
IL288755A
IL288755A IL288755A IL28875521A IL288755A IL 288755 A IL288755 A IL 288755A IL 288755 A IL288755 A IL 288755A IL 28875521 A IL28875521 A IL 28875521A IL 288755 A IL288755 A IL 288755A
Authority
IL
Israel
Prior art keywords
preparations
methods
biological substances
delivery carriers
carriers
Prior art date
Application number
IL288755A
Other languages
English (en)
Hebrew (he)
Original Assignee
Dnalite Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dnalite Therapeutics Inc filed Critical Dnalite Therapeutics Inc
Publication of IL288755A publication Critical patent/IL288755A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A61K47/6909—Micelles formed by phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5184—Virus capsids or envelopes enclosing drugs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Zoology (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Botany (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL288755A 2019-06-14 2021-12-07 Compositions and methods for biological delivery vehicles IL288755A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962861852P 2019-06-14 2019-06-14
US201962948095P 2019-12-13 2019-12-13
PCT/US2020/037579 WO2020252375A1 (en) 2019-06-14 2020-06-12 Compositions and methods for biological delivery vehicles

Publications (1)

Publication Number Publication Date
IL288755A true IL288755A (en) 2022-02-01

Family

ID=73781318

Family Applications (1)

Application Number Title Priority Date Filing Date
IL288755A IL288755A (en) 2019-06-14 2021-12-07 Compositions and methods for biological delivery vehicles

Country Status (8)

Country Link
US (1) US20220296516A1 (enExample)
EP (1) EP3982932A4 (enExample)
JP (1) JP7772597B2 (enExample)
CN (1) CN114286671A (enExample)
AU (1) AU2020290516C1 (enExample)
CA (1) CA3142949A1 (enExample)
IL (1) IL288755A (enExample)
WO (1) WO2020252375A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3864163T3 (da) 2018-10-09 2024-05-06 Univ British Columbia Sammensætninger og systemer omfattende transfektionskompetente vesikler fri for organiske opløsningsmidler og rengøringsmidler og fremgangsmåder forbundet dermed
WO2021119585A1 (en) * 2019-12-13 2021-06-17 Dnalite Therapeutics, Inc. Compositions and methods for biological delivery vehicles
WO2022260678A1 (en) * 2021-06-11 2022-12-15 Dnalite Therapeutics, Inc. Compositions and methods for biological delivery vehicles
TW202241388A (zh) * 2020-12-14 2022-11-01 美商Dna萊特治療公司 生物遞送系統
WO2022176953A1 (ja) * 2021-02-17 2022-08-25 国立大学法人北海道大学 脂質ナノ粒子
KR102789632B1 (ko) * 2021-04-01 2025-04-01 에스엔제이 파마 인크 생활성물질의 경구용 나노입자 및 이의 제조방법
WO2022211481A1 (ko) * 2021-04-01 2022-10-06 에스엔제이 파마 인크 생활성물질의 경구용 나노입자 및 이의 제조방법
AR127312A1 (es) * 2021-10-08 2024-01-10 Suzhou Abogen Biosciences Co Ltd Compuestos lipídicos ycomposiciones de nanopartículas lipídicas
EP4429644A1 (en) * 2021-11-12 2024-09-18 ModernaTX, Inc. Compositions for the delivery of payload molecules to airway epithelium
EP4497432A4 (en) * 2022-03-22 2025-07-30 Bion Inc PROTEIN DELIVERY COMPOSITION CONTAINING BILE SALT AND CATIONIC PEPTIDE AND USE THEREOF
CN117247359A (zh) * 2022-06-09 2023-12-19 中国科学院广州生物医药与健康研究院 一种树状样脂质化合物、脂质体、脂质复合物、脂质纳米颗粒及其应用
WO2024006863A1 (en) * 2022-06-30 2024-01-04 Precision NanoSystems ULC Lipid nanoparticle formulations for vaccines
CN118356505A (zh) * 2023-01-10 2024-07-19 复旦大学 含末端羟基的peg化纳米载体在制备规避人体预存抗peg抗体的药物制剂中的用途
KR20260030139A (ko) * 2023-06-28 2026-03-05 글로벌 라이프 사이언시즈 솔루션즈 캐나다 유엘씨 세포 요법을 위한 지질 나노입자 제형 및 관련 방법
WO2025021286A1 (en) * 2023-07-23 2025-01-30 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. A drug delivery system for increased endosomal escape
WO2025036297A1 (zh) * 2023-08-11 2025-02-20 浙江海昶生物医药技术有限公司 一种具有靶向性的脂质组合物及其制备方法
US20250082776A1 (en) * 2023-08-31 2025-03-13 Massachusetts Institute Of Technology Polyanion coated lipid nanoparticles and methods of use thereof
PL248770B1 (pl) * 2023-11-23 2026-01-26 Politechnika Wroclawska Bilosomy o dodatnim ładunku i sposób ich wytwarzania
WO2025151073A1 (en) * 2024-01-10 2025-07-17 Agency For Science, Technology And Research Composition and nanoparticle suitable for use in the delivery of a therapeutic agent

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100817024B1 (ko) * 2006-11-09 2008-03-26 재단법인 목암생명공학연구소 핵산 또는 약물을 간에 특이적으로 전달하는 복합체 및이를 포함하는 약학적 조성물
WO2010149785A1 (en) * 2009-06-26 2010-12-29 Universiteit Gent Cationic liposomes for the delivery of high molecular weight compounds
US20130017223A1 (en) * 2009-12-18 2013-01-17 The University Of British Columbia Methods and compositions for delivery of nucleic acids
EP2678350A1 (en) * 2011-02-22 2014-01-01 Leo Pharma A/S A cyclic peptide and conjugate thereof for binding to keratinocytes
JP7164950B2 (ja) * 2014-10-31 2022-11-02 ユニバーシティー オブ ユタ リサーチ ファウンデーション 胆汁酸粒子の組成物及び方法
EP3247328B1 (en) * 2015-01-21 2026-01-07 Genevant Sciences Gmbh Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells
KR20190093816A (ko) * 2016-10-26 2019-08-26 큐어백 아게 지질 나노입자 mRNA 백신
WO2018115527A2 (en) * 2016-12-23 2018-06-28 Curevac Ag Mers coronavirus vaccine
MX2020002348A (es) * 2017-08-31 2020-10-08 Modernatx Inc Métodos de elaboración de nanopartículas lipídicas.

Also Published As

Publication number Publication date
AU2020290516A2 (en) 2022-03-31
EP3982932A1 (en) 2022-04-20
AU2020290516B2 (en) 2026-01-29
CA3142949A1 (en) 2020-12-17
AU2020290516C1 (en) 2026-07-30
JP7772597B2 (ja) 2025-11-18
CN114286671A (zh) 2022-04-05
EP3982932A4 (en) 2023-10-25
AU2020290516A1 (en) 2022-01-20
US20220296516A1 (en) 2022-09-22
WO2020252375A1 (en) 2020-12-17
JP2022538797A (ja) 2022-09-06

Similar Documents

Publication Publication Date Title
IL281778A (en) Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies
IL282225A (en) Compositions and methods for immunotherapy
IL283840A (en) Compositions for the delivery of therapeutic agents and methods of use and making thereof
IL288909A (en) Methods of making bempedoic acid and compositions of the same
IL268788A (en) Compositions and methods for enhanced gene expression
IL270814A (en) Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
IL259246A (en) Compositions of therapeutic substances, methods and uses thereof
EP3743069C0 (en) BCL-2 PROTEIN-DEGRADING AGENTS FOR CANCER TREATMENT
IL269150A (en) Compositions and methods for treating cancer
IL281082A (en) Compositions of cxcr4 inhibitors and methods of preparation and use
IL281108A (en) Compositions and methods for enhancing donor oligonucleotide-based gene editing
IL280317A (en) Anti-avb8 antibodies and compositions and uses thereof
IL268814A (en) Compositions and methods for treatment of cancer
EP3471735A4 (en) PHARMACEUTICAL COMPOSITIONS AND THEIR USE FOR THE TREATMENT OF CANCER AND AUTOIMMUNE DISEASES
IL268872A (en) Methods and compositions for treating cancers using antisense
IL281015A (en) Methods and compositions for the modification of plants
EP3595681A4 (en) TRANSPLANT CELL-BASED IMMUNOTHERAPY FOR LONG-PERIOD ADMINISTRATION OF THERAPEUTIC PROTEIN
MA47119A (fr) Livraison de protéines au moyen de bactéries à virulence atténuée
IL282939A (en) Mixtures and compositions comprising 5-fluoro-4-imino-3- methyl-1-tosyl-3,4- dihydropyrimidin-2-one, and methods of use thereof
IL269157A (en) Compositions and methods for treating cancer
IL291725A (en) Methods and compositions for treating diabetic retinopathy
IL282251A (en) Compositions and methods for treatment of liver disease
IL280348A (en) Surface treatment compositions and methods
IL286811A (en) Compositions and methods for stabilizing protein-containing formulations
IL285039A (en) Compositions and methods for stimulating natural killer cells